1. Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1.
- Author
-
Langley, Joanne M., Gantt, Soren, Quach, Caroline, Bettinger, Julie A., Halperin, Scott A., Mutch, Jill, McNeil, Shelly A., Ward, Brian J., MacKinnon-Cameron, Donna, Ye, Lingyun, Marty, Kim, Scheifele, David, Brown, Erin, Alcantara, Joenel, and Canadian Immunization Research Network
- Subjects
- *
MENINGOCOCCAL vaccines , *YOUNG adults , *IMMUNIZATION of children , *MENINGOCOCCAL infections , *NEISSERIA meningitidis , *TEENAGERS , *ANTI-vaccination movement , *PREVENTION of epidemics , *RESEARCH , *IMMUNIZATION , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *MEDICAL protocols , *COMPARATIVE studies , *RANDOMIZED controlled trials , *STUDENTS , *GRAM-negative aerobic bacteria , *UNIVERSITIES & colleges , *BLIND experiment , *RESEARCH funding , *STATISTICAL sampling ,MEDICAL care for teenagers - Abstract
Emergency vaccination programs often are needed to control outbreaks of meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) on college campuses. Such campaigns expend multiple campus and public health resources. We conducted a randomized, controlled, multicenter, observer-blinded trial comparing immunogenicity and tolerability of an accelerated vaccine schedule of 0 and 21 days to a longer interval of 0 and 60 days for 4-component MenB vaccine (MenB-4C) in students 17-25 years of age. At day 21 after the first MenB-4C dose, we observed protective human serum bactericidal titers >4 to MenB strains 5/99, H44/76, and NZ 98/254 in 98%-100% of participants. Geometric mean titers increased >22-fold over baseline. At day 180, >95% of participants sustained protective titers regardless of their vaccine schedule. The most common adverse event was injection site pain. An accelerated MenB-4C immunization schedule could be considered for rapid control of campus outbreaks. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF